Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Niacinamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.85 |
| ▸ | F7 | P08709 | 1/20 | 0.85 |
| ▸ | F3 | P13726 | 1/20 | 0.85 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.85 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.85 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.85 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.85 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.85 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.85 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | APP | P05067 | 1/20 | 0.57 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.57 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.56 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Niacinamide SCHEMBL3690310 | 1.00 | SIRT2 (0.85) | SIRT2F7F3SARM1SIRT6 | |
| Niacinamide SCHEMBL29440775 | 1.00 | SIRT2 (0.85) | SIRT2F7F3SARM1SIRT6 | |
| Niacinamide SCHEMBL28378151 | 0.98 | SIRT2 (0.81) | SIRT2F7F3SARM1SIRT6 | |
| Niacinamide SCHEMBL28589383 | 0.92 | SIRT2 (0.85) | SIRT2F7F3SARM1SIRT6 | |
| Niacinamide SCHEMBL29624874 | 0.92 | — | — | |
| Niacinamide SCHEMBL19978192 | 0.92 | — | — | |
| Niacinamide SCHEMBL2926 | 0.92 | — | — | |
| Niacinamide SCHEMBL460466 | 0.92 | F7 (1.00) | SIRT2F7F3SARM1SIRT6 | |
| Niacinamide SCHEMBL25366418 | 0.90 | — | — | |
| Niacinamide SCHEMBL11870926 | 0.90 | F7 (0.96) | SIRT2F7F3SARM1SIRT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1324736-B1 | RAPID ANTIBIOTIC SUSCEPTIBILITY TEST | NAKANE DIAGNOSTICS INC (US) | 2009-05-13 | — | — | EP | claimed |
| EP-1324736-A4 | RAPID ANTIBIOTIC SUSCEPTIBILITY TEST | TRINE PHARMACEUTICALS INC (US) | 2005-07-20 | — | — | EP | claimed |
| US-20040156873-A1 | Topically Bioavailable Acne and Rosacea Treatment Compositions | GUPTA SHYAM K (US) | 2004-08-12 | — | — | US | claimed |
| US-20040081672-A1 | Niacinamide, niacin, and niacin esters based delivery systems for treating topical disorders of skin and skin aging | GUPTA SHYAM K (US) | 2004-04-29 | — | — | US | claimed |
| EP-1324736-A2 | RAPID ANTIBIOTIC SUSCEPTIBILITY TEST | Essential Therapeutics, Inc. (US) | 2003-07-09 | — | — | EP | claimed |
| WO-2002055015-A2 | RAPID ANTIBIOTIC SUSCEPTIBILITY TEST | ESSENTIAL THERAPEUTICS, INC. (US) | 2002-07-18 | — | — | WO | claimed |
| CN-119700686-A | NAD (NAD)+Freeze-dried powder injection and its preparation process | 康诺生物制药股份有限公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-119453476-A | Preparation method of anti-aging compound nutrient containing coenzyme and bioactive hydrogen | 何淑珍 | 2025-02-18 | — | — | CN | disclosed |
| CN-119386053-A | Method for preparing artificial bear gall powder by using black chicken gall | 江西邦泰绿色生物合成生态产业园发展有限公司 | 2025-02-07 | — | — | CN | disclosed |
| CN-118845611-A | Preparation and application of gel for promoting muscle growth | 四川农业大学 | 2024-10-29 | — | — | CN | disclosed |
| CN-115813795-B | Anti-wrinkle composition and application thereof | 泉后(广州)生物科技研究院有限公司 | 2024-10-18 | — | — | CN | disclosed |
| CN-118542845-A | NMN resveratrol capsule | 宝利化（南京）制药有限公司 | 2024-08-27 | — | — | CN | disclosed |
| CN-118542842-A | NMN resveratrol sustained release tablet | 宝利化（南京）制药有限公司 | 2024-08-27 | — | — | CN | disclosed |
| US-20060039887-A1 | Cosmetic or pharmaceutical composition for skin care | INFINITY2 HEALTH SCIENCES, INC. | 2006-02-23 | — | — | US | disclosed |
| EP-1324736-A4 | RAPID ANTIBIOTIC SUSCEPTIBILITY TEST | TRINE PHARMACEUTICALS INC (US) | 2005-07-20 | — | — | EP | disclosed |
| US-20040228884-A1 | Ion-pair delivery system for cosmetic and pharmaceutical compositions | GUPTA SHYAM K (US) | 2004-11-18 | — | — | US | disclosed |
| EP-1324736-A2 | RAPID ANTIBIOTIC SUSCEPTIBILITY TEST | Essential Therapeutics, Inc. (US) | 2003-07-09 | — | — | EP | disclosed |
| WO-2002055015-A2 | RAPID ANTIBIOTIC SUSCEPTIBILITY TEST | ESSENTIAL THERAPEUTICS, INC. (US) | 2002-07-18 | — | — | WO | disclosed |
| US-4368194-A | ANTIINFLAMMATORY, ANTIARTHRITIC | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1983-01-11 | — | — | US | disclosed |
| US-4312989-A | Pharmacologically active amine boranes | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1982-01-26 | — | — | US | disclosed |